



Supplement



Supplemental Figure 1: Early-onset pathways. Visualization of overrepresented pathways (yellow) was performed using the Reactome online analysis tool (Version 87, human targets). *In vitro* validated targets of miRNAs miR-21-5p, miR-29b-3p, miR-34a-5p, miR-126-3p, and miR-132-3p were submitted to determine pathway enrichment. Darker shades indicate lower p values.



Supplemental Figure 2: Late-onset pathways. Visualization of overrepresented pathways (yellow) was performed using the Reactome online analysis tool (Version 87, human targets). *In vitro* validated targets of miRNAs miR-146a-5p and miR-221-3p were submitted to determine pathway enrichment. NOD1/2, RHOH, and FASL/CD95L are marked by red circles. Darker shades indicate lower p values.